The Foolish bottom line PDL BioPharma exhibits a fairly clean – if fleeting -- dividend bill of health. It has a modest payout ratio and manageable debt. Dividend investors should be aware that the company's whopping yield has a lot to do with the fact that the company is in wind-down mode.